Dual-specificity kinase DYRK3 phosphorylates p62 at the Thr-269 residue and promotes melanoma progression

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Melanoma is a complex skin cancer influenced by genetic and environmental factors.
• Dual-specificity tyrosine-phosphorylation-regulated kinases (DYRKs) regulate critical cellular processes.
• The specific role of DYRK3 in melanoma remains largely uncharacterized.

Purpose of the Study:

• To investigate the interaction between DYRK3 and p62 in melanoma.
• To elucidate the functional consequences of DYRK3-p62 interaction on melanoma progression.
• To explore the potential of targeting this pathway for melanoma therapy.

Main Methods:

• Investigated DYRK3-p62 interaction using biochemical assays.
• Analyzed the effect of DYRK3-mediated p62 phosphorylation on downstream signaling.
• Utilized cell culture models of melanoma to assess the impact on cell growth, migration, and colony formation.
• Employed DYRK3 knockdown and specific phosphorylation blockade strategies.

Main Results:

• DYRK3 directly phosphorylates p62 at Ser-207 and Thr-269.
• Phosphorylation of p62 at Thr-269 enhances its interaction with TRAF6, activating mTORC1.
• DYRK3-mediated p62 phosphorylation promotes melanoma cell growth, colony formation, and migration.
• Inhibition of DYRK3 or p62-T269 phosphorylation suppressed melanoma progression.

Conclusions:

• DYRK3 phosphorylates p62, activating the p62-TRAF6-mTORC1 pathway in melanoma.
• This pathway positively modulates melanoma cell growth and progression.
• Targeting DYRK3 or p62 phosphorylation represents a potential therapeutic strategy for melanoma.